Home > > > > > Report Detail

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 29-Apr-2022
No. of pages: 632
Inquire Before Buying

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2022, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 13, 42, 37, 3, 77 and 37 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 1, 1, 4 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Crohn's Disease (Regional Enteritis) - Overview
Crohn's Disease (Regional Enteritis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
Crohn's Disease (Regional Enteritis) - Drug Profiles
Crohn's Disease (Regional Enteritis) - Dormant Projects
Crohn's Disease (Regional Enteritis) - Discontinued Products
Crohn's Disease (Regional Enteritis) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2022: People with moderate to severe uncontrolled Crohn's disease granted early access to new investigational treatment in the UK
Apr 04, 2022: Thetis Pharmaceuticals secures $4.2 million from the Helmsley Charitable Trust to advance its first-in-class Resolvin oral therapy for Crohn's Disease
Mar 30, 2022: Redx nominates GI-targeted ROCK inhibitor, RXC008, as clinical development candidate
Mar 28, 2022: Tiziana commences Phase Ib trial of Crohn's disease antibody
Mar 24, 2022: Celltrion Healthcare wins tender to supply Remsimato the Brazilian Federal Government
Feb 28, 2022: AbbVie provides update regarding SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in the U.S.
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
Feb 20, 2022: Rapid improvement and remission in patients with refractory ulcerative colitis and crohn's colitis after direct injection of Remestemcel-L by colonoscopy
Feb 18, 2022: The majority of adults with moderately to severely active Crohn's disease in a phase 2 study achieved clinical remission and corticosteroid-free remission through 48 weeks with TREMFYA (guselkumab)
Feb 15, 2022: Statera Biopharma announces Central Institutional Review Board approval of phase 3 clinical trial for pediatric Crohn's disease
Feb 04, 2022: Tiziana announces submission of amendment to Investigational New Drug Application to advance oral foralumab, a fully human anti-CD3 monoclonal antibody, in patients with crohn's disease
Feb 04, 2022: Mitsubishi Tanabe's 9 month sales rise fueled by strong growth in Stelara
Jan 06, 2022: Avalo reports positive phase 1b results for AVTX-002 in moderate to severe Crohn's disease patients and Presents Additional Program Updates at 2022 Investor Event
Dec 29, 2021: Statera Biopharma submits phase 3 clinical trial protocol to FDA for investigational treatment of pediatric Crohn's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Crohn's Disease (Regional Enteritis) - Dormant Projects, 2022
Crohn's Disease (Regional Enteritis) - Discontinued Products, 2022
Crohn's Disease (Regional Enteritis) - Discontinued Products, 2022 (Contd..1)

List of Figures
Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
  • Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period. The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
  • Global Lansoprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 102
    The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period. The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
  • Global Esomeprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 89
    The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Irritable Bowel Syndrome (IBS) market: According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
  • Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Diarrhea Drug market: According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
  • Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
  • Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 136
    Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
  • Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Pentasa (Ulcerative Colitis) market: According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs